Q32 Bio

QTTB

Biotechnology · Healthcare

Price

$15.05

-0.16 (-1.05%)

Market Cap

$192.3M

Exchange

NASDAQ

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Share count rising — dilution

+301.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 3.1M (2021) → 12.3M (2025)

Q32 Bio is a small biotechnology company focused on developing drugs that treat diseases caused by an overactive immune system. Its main focus is on conditions like atopic dermatitis (a severe form of eczema) and other inflammatory diseases. The company is working on experimental medicines that have not yet been approved, so it does not sell products to regular customers yet.

Q32 Bio makes almost no revenue from product sales right now. Instead, it funds its work through partnerships, grants, and money raised from investors. It operates primarily in the United States and has a market value of around $200 million, which is small even by biotech standards. The company's main risk is that its drugs must still pass clinical trials and win approval from the FDA before they can be sold — a process that is expensive, slow, and often fails.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+40.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$19M/ year

↓ Declining (-60% vs prior year)

35.6% of revenue

2.0x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

49.9%ownership

Insiders own a meaningful stake in the company

Cash Runway

~2 years

$51M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-13.5%

Weak — -13.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

Data not available

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

-82%

Weak — only -82% of profit becomes cash

FCF Margin

-51.0%

Burning cash (-51.0%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.24

Conservative — low debt load (0.24)

Interest Cover

21.41x

Comfortably covers interest (21.4x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

5.6x

Attractive valuation — P/E 5.6

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial